TABLE 2.
Phenotypic and genotypic properties of 41 MRSA isolates belonging to minor clones or sporadic isolates present in hospitals
| Country and strain | Yr of isolation | Antibiograma
|
Clonal type | spaA type | ST | MLST | CCb | SCCmec typec | ccr type | mec complex | luk-PVd | Doubling time (min)e | Source or reference | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PEN | OXA | ERY | GEN | CLI | CHL | CIP | RIF | TET | SXT | VAN | |||||||||||||
| Portugal | |||||||||||||||||||||||
| HSA10 | 1992 | R | R | R | R | R | S | S | S | R | S | S | III::α::A | WGKAOM | 239 | 2-3-1-1-4-4-3 | 8 | NT-III | 3 | A | − | 32.85 | 5 |
| HSA49 | 1993 | R | R | S | R | S | S | R | S | S | S | S | V::NH::B | TJMBMDMGMK | 5 | 1-4-1-4-12-1-10 | 5 | IV | 2 | B | − | 25.96 | 5 |
| HGSA9 | 1997 | R | R | R | R | S | S | R | I | S | R | S | XI::B::g | Nontypeable | 239 | 2-3-1-1-4-4-3 | 8 | IIIA | − | 26.62 | 5 | ||
| HGSA128 | 2000 | R | R | R | S | S | S | R | S | S | S | S | XI::NH::D1 | TJJEJNI2MNI2MOMOKR | 79 | 7-6-1-33-8-8-6 | 22 | IV | 2 | B | − | 25.02 | 5 |
| IPOP2 | 2001 | R | R | R | S | S | S | R | S | S | S | S | II::NA::D2 | TJJEJNI2MN12MOMOKR | 22 | 7-6-1-5-8-8-6 | 22 | IV | 2 | B | − | 29.12 | This study |
| Italy | |||||||||||||||||||||||
| ITL262 | 1997 | R | R | S | R | S | S | R | R | R | S | S | II::NH::E | YHFGFMBQBLO | 247 | 3-3-1-12-4-4-16 | 8 | I | − | 26.97 | -f | ||
| ITL592 | 1998 | R | R | R | R | R | S | R | R | S | S | S | II::E::F | TIMBMDMBMDMGMK | 228 | 1-4-1-4-12-24-29 | 5 | I | − | 34.66 | - | ||
| ITL113 | 1997 | R | R | R | R | R | R | R | R | S | S | S | II::E::G | TIMBMBMDMGMK | 228 | 1-4-1-4-12-24-29 | 5 | I | − | 30.94 | - | ||
| Turkey | |||||||||||||||||||||||
| TUR4 | 1996 | R | R | I | R | S | S | R | R | R | S | S | II::ηη::H | WGKAQQ | 239 | 2-3-1-1-4-4-3 | 8 | III | − | 29.62 | This study | ||
| TUR9 | 1995 | R | R | R | R | R | S | R | R | R | S | S | III::A::I2 | WGKAQQ | 239 | 2-3-1-1-4-4-3 | 8 | III | − | 31.65 | This study | ||
| TUR1 | 1996 | R | R | R | R | S | R | R | R | R | S | S | III::A::J | WGKAQQ | 239 | 2-3-1-1-4-4-3 | 8 | III | − | 27.84 | This study | ||
| TUR27 | 1996 | R | R | R | R | S | S | R | R | R | S | S | II::D::II | WGKAQQ | 239 | 2-3-1-1-4-4-3 | 8 | III | − | 30.01 | This study | ||
| Greece | |||||||||||||||||||||||
| GRE14 | 1998 | R | R | S | S | R | S | S | S | S | S | S | II::NH::K | UJGBBPB | 80 | 1-3-1-14-11-51-10 | S | IV | 2 | B | + | 26.56 | 1 |
| GRE120 | 1993 | R | R | R | R | S | S | S | S | R | R | S | II::E::L | YGFMBQBLPO | 8 | 3-3-1-1-4-4-3 | 8 | IV | 2 | B | − | 30.27 | 1 |
| GRE108 | 1998 | R | R | R | R | R | S | S | R | R | R | S | III::B::M | XKAOMMQ | 239 | 2-3-1-1-4-4-3 | 8 | III | − | 32.24 | 1 | ||
| Czech Republic | |||||||||||||||||||||||
| CR1 | 1996 | R | R | S | S | S | R | S | S | S | S | S | II::NH::N | YGFMBQBLO | 8 | 3-3-1-1-4-4-3 | 8 | IV | 2 | B | − | 25.67 | 23 |
| CR43 | 1996 | R | R | R | R | R | R | S | S | R | S | S | I::NH::O | YHGFMBQBLO | 8 | 3-3-1-1-4-4-3 | 8 | IV | 2 | B | − | 33.81 | 23 |
| Poland (PLN49) | 1997 | R | R | S | S | S | S | S | S | R | S | S | II::NH::P | XKAKBEMBKB | 45 | 10-14-8-6-10-3-2 | 45 | IV | 2 | B | − | 27.18 | 20 |
| Chile | |||||||||||||||||||||||
| CHL5 | 1997 | R | R | R | R | R | R | R | S | S | R | S | II::E′::Q2 | TMK | 83 | 1-4-1-4-12-1-1 | 5 | I | − | 33.32 | 4 | ||
| CHL63 | 1997 | R | R | R | R | R | R | R | I | I | S | S | II::E::Q1 | TIMEMDMGMGMK | 5 | 1-4-1-4-12-1-10 | 5 | I | − | 31.22 | 4 | ||
| Colombia (COB111) | 1998 | R | R | R | S | S | S | R | S | S | S | S | II::NH::R | JCMBPB | 84 | 1-26-28-32-18-33-27 | 91 | IV | 2 | B | − | 30.81 | 18 |
| Argentina | |||||||||||||||||||||||
| ARG33 | 1996 | R | R | R | R | S | R | R | R | S | S | S | II::E::S | TIMBMDMGMK | 85 | 31-4-1-4-12-1-10 | 5 | IIIA | − | 31.94 | 7 | ||
| ARG127 | 1995 | R | R | S | R | S | S | S | S | S | S | S | II::NH::T | WGKAKAOMQQ | 30 | 2-2-2-2-6-3-2 | 30 | IVA | 2 | B | − | 34.15 | 7 |
| ARG229 | 1995 | R | R | S | R | S | S | S | S | S | S | S | I::NH::U | TJMBMDMGMK | 100 | 1-65-1-4-12-1-10 | 5 | IV-new1 | 2 | None | − | 30.67 | 7 |
| ARG199 | 1996 | R | R | R | S | S | S | S | S | S | S | S | I::NH::V | UJGFGMDMGGM | 86 | 2-4-1-8-4-4-3 | 8 | IVA-new1 | 2 | None | − | 28.18 | 7 |
| ARG64 | 1996 | R | R | R | R | S | R | R | R | R | R | S | II::EE::X | TIMBMDMGMK | 85 | 31-4-1-4-12-1-10 | 5 | I | − | 35.91 | 7 | ||
| ARG105 | 1995 | R | R | R | R | S | S | R | I | R | S | S | II::E::WI | YHFGFMBQBLO | 247 | 3-3-1-12-4-4-16 | 8 | IV-new2 | None | None | − | 35.01 | 7 |
| AGT42 | 1996 | R | R | R | R | R | R | R | R | S | S | S | IX::OO::Y | TIMBMDMGMK | 5 | 1-4-1-4-12-1-10 | 5 | I | − | 30.54 | 4 | ||
| AGT30 | 1996 | R | R | R | R | R | S | R | R | R | S | S | XI::E::W2 | YHFGFMBQBLO | 247 | 3-3-1-12-4-4-16 | 8 | IV-new2 | None | None | − | 30.54 | 4 |
| AGT55 | 1996 | R | R | R | R | S | S | S | R | S | S | S | IX::E::a | UMDJMGMK | 5 | 1-4-1-4-12-1-10 | 5 | I | − | 28.18 | 4 | ||
| Brazil | |||||||||||||||||||||||
| BZ40 | 1996 | R | R | R | R | R | S | S | R | S | R | S | I::E::Z1 | TMK | 5 | 1-4-1-4-12-1-10 | 5 | I | − | 29.62 | 4 | ||
| BZ48 | 1997 | R | R | R | R | R | R | R | S | R | R | S | III::B::C1 | Nontypeable | 239 | 2-3-1-1-4-4-3 | 8 | IIIA | − | 34.31 | 4 | ||
| BZ14 | 1996 | R | R | I | R | S | S | S | R | S | R | S | II::E::Z1 | TMK | 5 | 1-4-1-4-12-1-10 | 5 | I | − | 29.75 | 4 | ||
| Japan | |||||||||||||||||||||||
| JP84 | 1997 | R | R | R | S | S | S | R | S | S | S | S | I::J::b | YHHGFMBQQBLO | 8 | 3-3-1-1-4-4-3 | 8 | I | − | 27.51 | 3 | ||
| JP82 | 1997 | R | R | S | R | S | S | S | S | S | S | S | I′::NH::c | EJCMBPB | 92 | 1-26-28-18-18-54-27 | 91 | IVA | 2 | B | − | 28.64 | 3 |
| JP87 | 1997 | R | R | R | S | R | S | S | S | S | S | S | I::A::d | EJCMBPB | 89 | 1-26-28-18-18-33-50 | 91 | II′ | 2 | A | − | 27.95 | 3 |
| JP26 | 1997 | R | R | R | S | R | S | R | S | S | S | S | I::A::e | TJMBMDMGMK | 5 | 1-4-1-4-12-1-10 | 5 | II | − | 24.93 | 3 | ||
| JP238 | 1998 | R | R | R | R | S | S | I | S | S | S | S | I::A::f | TDMGMK | 5 | 1-4-1-4-12-1-10 | 5 | II′′ | 2 | A | − | 27.84 | 3 |
| Taiwan | |||||||||||||||||||||||
| TAW97 | 1998 | R | R | R | R | R | R | R | R | R | R | S | XI::B::C2 | WGKAOMQ | 239 | 2-3-1-1-4-4-3 | 8 | IIIA | − | 34.48 | 2 | ||
| TAW214 | 1998 | R | R | R | R | R | R | S | S | S | S | S | II::NH::h | ZDMDMOB | 59 | 19-23-15-2-19-20-15 | S | IV | 2 | B | − | 28.41 | 2 |
| TAW166 | 1998 | R | R | R | R | R | R | S | R | R | S | S | II::ZZ::j | Nontypeable | 81 | 3-32-1-1-4-4-3 | 8 | NT-IV | 2 | B | − | 34.31 | 2 |
a
Antibiotic abbreviations: PEN, penicillin; OXA, oxacillin; ERY, erythromycin; GEN, gentamicin; CLI, clindamycin; CHL, chloramphenicol; CIP, ciprofloxacin; RIF, rifampin; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole; VAN, vancomycin. A few isolates were tested for fusidic acid and teicoplanin resistance. R, resistant, S, susceptible; I, intermediate.
b
Based on BURST. S, singleton (not assigned to any clonal complex).
c
NT, isolate considered nontypeable by the multiplex strategy due to extra or missing amplification fragments relatively to the described patterns.
d
luk-PV genes encode PVL. +, presence of PVL determinant; −, absence of PVL determinant.
e
Doubling time during exponential growth phase.
f
-, R. Mato et al., unpublished data.